Adolor (ADLR) Coverage Resumed with Buy Rating at Brean Murray

Coverage of Adolor (ADLR) has been resumed today by the research analysts at investment firm Brean Murray.  Brean Murray resumes this coverage of ADLR with an increased price target set at $4 dollars,  it had originally been $3 dollars.  Brean Murray analysts carry a performance outlook on ADLR of “buy.”

Adolor is slated to release their next earnings report on July 28th, 2011 and is estimated to post negative EPS of 16 cents  Their last earnings report was released on April 28th, 2011 and announced negative EPS of 16 cents with revenue totaling $7.5 million which was up 41.5 % year to year.  ADLR is currently trading above its 50 & 200-day moving averages and 2011 is currently an up year for the company.

Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription pain and pain-management products.  The company has market capitalization of $7,024,000,000 and 82,890,000 shares outstanding.  ADLR has a 52-week high of $1.74 with the low being an even $1 dollar.



Latest News

Tingyi   vs. ITOCHU CORP/ADR  Financial Contrast
Tingyi vs. ITOCHU CORP/ADR Financial Contrast
Zacks: International Speedway Corp  Receives Average Rating of “Hold” from Brokerages
Zacks: International Speedway Corp Receives Average Rating of “Hold” from Brokerages
Citigroup Cuts Magna International  Price Target to $62.00
Citigroup Cuts Magna International Price Target to $62.00
Investors Buy Large Volume of Put Options on Sumitomo Mitsui Financial Grp
Investors Buy Large Volume of Put Options on Sumitomo Mitsui Financial Grp
Baytex Energy  Trading Down 6.5%
Baytex Energy Trading Down 6.5%
CorePoint Lodging  Lifted to “Hold” at Zacks Investment Research
CorePoint Lodging Lifted to “Hold” at Zacks Investment Research


© 2006-2019 Ticker Report